一例伴嚴重高甘油三酯血癥的特殊類型糖尿病的臨床應對_West China Medical Journal

Authors：

乙豐收 ¹ , 朱玉倩 ¹ ,  譚惠文 ^2,3 , 阿布杜 ¹ , 伊力哈木 ¹ ,  黃雪芳 ^1,2

1. ;
2. ;
3. ;

Corresponding?author：

譚惠文, Email: huiwent2016@scu.edu.cn; 黃雪芳, Email: huangxuefang2323@163.com

Keywords：

脂代謝紊亂; 高甘油三酯血癥; 特殊類型糖尿病; 非諾貝特

DOI：

10.7507/1002-0179.201811119

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 乙豐收, 朱玉倩, 譚惠文, 阿布杜, 伊力哈木, 黃雪芳. 一例伴嚴重高甘油三酯血癥的特殊類型糖尿病的臨床應對. West China Medical Journal, 2019, 34(4): 472-474. doi: 10.7507/1002-0179.201811119 Copy

1.	Jing, Pang, Dick, et al. Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World J Diabetes, 2014, 5(2): 165-175.
2.	諸駿仁, 高潤霖, 趙水平, 等. 中國成人血脂異常防治指南. 中華心血管病雜志, 2007, 16(5): 390-419.
3.	National Cholesterol Education Program (NCEP). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation, 2002, 106(25): 3143-3421.
4.	Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol, 2014, 2(8): 655-666.
5.	Duerden M, O’Flynn N, Qureshi N. Cardiovascular risk assessment and lipid modification: NICE guideline. Br J Gen Pract, 2015, 65(636): 378-380.
6.	Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2012, 97(9): 2969-2989.
7.	Karalis DG. A review of clinical practice guidelines for the management of hypertriglyceridemia: a focus on high dose omega-3 fatty acids. Adv Ther, 2017, 34(2): 300-323.
8.	Berglund L, Brunzell JD, Goldberg AC, et al. Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab, 2014, 28(3): 423-437.
9.	Rajamani K, Colman PG, Li PL, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet, 2009, 373(9677): 1780-1788.
10.	ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010, 363(3): 233-244.
11.	Retterst?l K, Narverud I, Selmer R, et al. Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics. Lipids Health Dis, 2017, 16(1): 115.
12.	Bonds DE, Craven TE, Buse J, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia, 2012, 55(6): 1641-1650.

1. Jing, Pang, Dick, et al. Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World J Diabetes, 2014, 5(2): 165-175.
2. 諸駿仁, 高潤霖, 趙水平, 等. 中國成人血脂異常防治指南. 中華心血管病雜志, 2007, 16(5): 390-419.
3. National Cholesterol Education Program (NCEP). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation, 2002, 106(25): 3143-3421.
4. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol, 2014, 2(8): 655-666.
5. Duerden M, O’Flynn N, Qureshi N. Cardiovascular risk assessment and lipid modification: NICE guideline. Br J Gen Pract, 2015, 65(636): 378-380.
6. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2012, 97(9): 2969-2989.
7. Karalis DG. A review of clinical practice guidelines for the management of hypertriglyceridemia: a focus on high dose omega-3 fatty acids. Adv Ther, 2017, 34(2): 300-323.
8. Berglund L, Brunzell JD, Goldberg AC, et al. Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab, 2014, 28(3): 423-437.
9. Rajamani K, Colman PG, Li PL, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet, 2009, 373(9677): 1780-1788.
10. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010, 363(3): 233-244.
11. Retterst?l K, Narverud I, Selmer R, et al. Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics. Lipids Health Dis, 2017, 16(1): 115.
12. Bonds DE, Craven TE, Buse J, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia, 2012, 55(6): 1641-1650.

Previous Article
運動后髂內動脈分支破裂后患者的康復治療一例

West China Medical Journal

一例伴嚴重高甘油三酯血癥的特殊類型糖尿病的臨床應對

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content